Use of three-dimensional computed tomography overlay for real-time cryoballoon ablation in atrial fibrillation reduces radiation dose and contrast dye

B. Oude Velthuis 1 · M. Molenaar 1 · H. G. Reinhart Dorman 2 · J. Y. Stevenhagen 1 · M. F. Scholten 1 · J. van der Palen 3, 4 · J. M. van Opstal 1

Published online: 15 February 2017
© The Author(s) 2017. This article is available at SpringerLink with Open Access.

Abstract

Aims Cryoballoon pulmonary vein (PV) isolation in patients with atrial fibrillation has proven to be effective in short-term and long-term follow-up. To visualise the PV anatomy, pre-ablation contrast pulmonary venography is commonly performed. Three-dimensional (3D) computed tomography (CT) overlay is a new technique creating a live 3D image of the left atrium by integrating a previously obtained CT scan during fluoroscopy. To evaluate the benefits of 3D CT overlay during cryoballoon ablation, we studied the use of 3D CT overlay versus contrast pulmonary venography in a randomised fashion in patients with paroxysmal atrial fibrillation undergoing cryoballoon PV isolation.

Methods and results Between October 2012 and June 2013, 30 patients accepted for PV isolation were randomised to cryoballoon PV isolation using either 3D CT overlay or contrast pulmonary venography. All patients underwent a pre-procedural cardiac CT for evaluation of the anatomy of the left atrium (LA) and the PVs. In the 3D CT overlay group, a 3D reconstruction of the LA and PVs was made. An overlay of the CT reconstruction was then projected over live fluoroscopy. Patients in the contrast pulmonary venography group received significantly more contrast agent (77.1 ± 21.2 cc vs 40.1 ± 17.6 cc, p < 0.001) and radiation (43.0 ± 21.9 Gy.cm² vs 28.41 ± 11.7 Gy.cm², p = 0.04) than subjects in the 3D CT overlay group. There was no difference in total procedure time, fluoroscopy time and the amount of cryoapplications between the two groups.

Conclusion The use of 3D CT overlay decreases radiation and contrast dye exposure and can assist in guiding cryoballoon-based PV isolation.

Keywords Atrial fibrillation · Pulmonary vein isolation · Ablation · Cryoballoon

Introduction

Atrial fibrillation (AF) is the most common arrhythmia, affecting approximately 1.5–2% of the general population [1]. In 1998, the pulmonary veins (PVs) were identified as potential targets for the invasive treatment of AF [2]. PV isolation is an effective treatment for patients with symptomatic paroxysmal AF and recommended in international guidelines [1]. Ablation success rates at 12 months range between 66 and 89% [3–5]. However, radiofrequency ablation requires tedious point-to-point delivery of multiple applications to isolate PVs [6]. As a result, more circular ablation catheters have been developed facilitating PV isolation. Ablation using a cryoballoon has been proven effective in short and long-term follow-up, with equal efficacy and safety, compared with the conventional radiofrequency approach [6–10].

Pre-procedural contrast pulmonary venography is commonly performed to visualise the PV anatomy. Fluoroscopy is inherently associated with significant radiation exposure for both the patient and operator. Improved visualisation using iodine-based contrast agents is dose-dependent re-
lated to acute and chronic kidney failure. Several techniques have been evaluated to optimise the visualisation during the cryoablation procedure, such as the use of real-time three-dimensional oesophageal echocardiography [11].

Three-dimensional (3D) computed tomography (CT) overlay creates a live 3D image during the procedure by integrating fluoroscopy with a previous CT scan or newly taken rotational angiographic 3D images of the left atrium (LA) and it has been shown to assist in radiofrequency-based PV isolation [12]. 3D CT overlay can facilitate optimal positioning of the cryoballoon and reduce contrast medium use and radiation exposure. Better positioning of the balloon can decrease the necessity for additional application(s) during PV isolation, using extra balloon or catheter cryoapplications to achieve PV isolation. To evaluate the benefits of 3D CT overlay during cryoballoon ablation, we studied the use of 3D CT overlay versus contrast pulmonary venography in a randomised fashion in consecutive patients with paroxysmal AF undergoing cryoballoon PV isolation.

Methods

Patients were eligible for enrolment in the study when they were accepted for percutaneous PV isolation for paroxysmal AF, as defined in the current guidelines [1]. The exclusion criteria were as follows: (1) Patients with persistent AF, as defined in the current guidelines [13]; (2) A left atrial diameter of more than 50 mm in the parasternal long axis on transthoracic echocardiography; (3) Previous pulmonary vein isolation ablation (epicardial or endocardial); (4) Previous cardiac surgery; (5) Significant valvular disease present on echo (mitral or aortic valve regurgitation above grade 2, moderate to severe mitral or aortic stenosis); (6) Concomitant cardiac surgery needed; (7) Left ventricular ejection fraction <40%; (8) Hypertrophic (obstructive) cardiomyopathy or dilated cardiomyopathy defined as an ejection fraction <40%; (9) Pregnancy; (10) Myocardial infarction within the previous 3 months; (11) AF secondary to electrolyte imbalance, thyroid disease, other reversible or non-cardiovascular causes for AF. Patients were recruited in the outpatient clinic and included in the study after signed informed consent was obtained.

After inclusion, patients were randomised to cryoballoon PV isolation using 3D CT overlay or contrast pulmonary venography. All patients underwent a pre-procedural cardiac CT for evaluation of the anatomy of the LA and the PVs. If the patient’s PV anatomy was not suitable for cryoballoon ablation, the patient was excluded. Patients were also excluded if the PVs could not be isolated with the cryoballoon alone during the procedure.

Sample size calculation

To reach statistical significance of 20% difference between the two groups regarding fluoroscopy time and contrast medium, we used the following parameters for power calculation: alpha = 5%; power = 80%; and assuming equal standard deviations in each group. Requiring 47 patients for fluoroscopy time and 17 for contrast medium. An interim analysis would be performed after 30 inclusions in consultation with the medical research ethics committee.

Pre-procedural cardiac CT

The pre-procedural contrast-enhanced cardiac CT was performed using a 64 multi-slice scanner (Toshiba Aquilion 64, Tokyo, Japan). Images were obtained at 120 kV and 300 mAs. Rotation time was 0.4 ms. The thickness of the reconstructed image slices was 0.3 mm. During a 20-second end/expiratory breath hold, 80 ml contrast (Visipaque 320, GE Healthcare A.S., Oslo, Norway) was injected. An ECG-triggered scan was timed at 50% of the average inter-beat (RR) interval.

Ablation procedure

Two electrophysiologists (MS and JvO) with extensive experience in cryoballoon ablation performed the procedures. All patients were on oral vitamin-K antagonists with the international normalised ratio between 2.5 and 3.5. Vitamin K antagonists were continued during the procedure [14]. All procedures were performed under general anaesthesia and arterial blood pressure was continuously monitored. Venous access was obtained from the right and left femoral vein. A diagnostic catheter (EP XT CS 4p, BARD Medical Inc., GA, USA) was positioned in the coronary sinus for stimulation of the LA. The LA was accessed by a transseptal puncture with a Brockenbrough needle monitored by intracardiac echocardiography (St. Jude Medical, MN, USA), first with a SL-O sheath (St. Jude Medical, MN, USA), changed over a 0.32 F wire to a steerable 12 F sheath (Flexcath, Medtronic Inc., MN, USA). During the procedure, heparin was given to achieve an activated clotting time of >350 s. The use of a 23 or 28 mm balloon was based on the PV diameters.

3D CT overlay group

Before the start of the procedure, the CT images were imported into the EP Navigator workstation (Philips Medical Systems, Best, the Netherlands) to create a 3D digital reconstruction of the anatomy of the LA and the PVs as previously described [12]. An automated reconstruction tool was used. Manual correction tools were used for optimisation.
of this reconstruction. An overlay of the CT reconstruction was then applied over live fluoroscopy and registration was performed using anatomical landmarks, catheter positions and contrast boluses in both superior PVs. Validation of the correct registration was performed in anteroposterior and lateral views (Fig. 1).

Contrast pulmonary venography group

After transseptal puncture, a 7 French NIH catheter (Cordis, Miami Lakes, FL, USA) was introduced and contrast was delivered to each single PV. High definition cinemographic images of the PVs were made in left and right anterior oblique projections.

Procedure

We used the Arctic Front Advance cryoballoon (Arctic Front Advance, Medtronic Inc., MN, USA). The 28-mm balloon was used in 21 patients. A multipolar catheter (Achieve, Medtronic Inc., MN, USA) was inserted through the inner lumen of the balloon to assess PV signals before, during and after the ablation and to guide the positioning of the balloon, after which the total assembly was introduced into the LA. After inflation, the cryoballoon was advanced to occlude the PV and a contrast bolus was administered to confirm total occlusion. In general, two consecutive applications were delivered for each PV, varying from 180 to 240 s, depending on temperatures reached. During isolation of the right PVs, the right phrenic nerve was continuously stimulated by a catheter placed in the superior vena cava. If the diaphragm excursions diminished during cryoablation, the ablation was immediately stopped using the double stop technique [15]. Bidirectional block was confirmed for each vein. After a 30-minute waiting period, all four PVs were checked for reconduction and adenosine was administered to reveal dormant PV potentials.

Radiation dose

Effective dose is a convenient quantity to estimate the stochastic risk of radiation applied to patients in interventional procedures [16]. Radiation of cardiac CT was measured as dose length product. The dose length product was converted to the effective dose by using a conversion factor of 0.014 mSv Gy1 cm1 [17]. Radiation of fluoroscopy was measured in dose area product (DAP). The DAP was converted to the effective dose by using a conversion coefficient of 0.188 mSv Gy1 cm2 [18]. For the 3D CT overlay group, the main effective dose was calculated by adding the previously mentioned conversion indices for the cardiac CT and radiation of fluoroscopy.

Procedure time, number of applications, radiation exposure and contrast agent

The total procedure time was defined as the total time between the first puncture of the femoral vein and the end of the procedure. The following were documented: (1) The time from the first puncture of the femoral vein to the transseptal puncture; (2) The total number of cryoballoon applications; (3) The total fluoroscopy time; (4) The total radiation dose; and (5) The total amount of contrast agent used. We registered the total amount of contrast used for any kind of image enhancement and for determination of the grade of occlusion during cryoablation. We therefore reported contrast usage in both groups for any reason other than visualising the PVs. In the pulmonary venography group, the amount of contrast agent used for PV visualisation alone was also registered.

Follow-up

After the intervention, patients were scheduled for four outpatient clinic visits at 1, 3, 6 and 12 months. Antiarrhythmic drugs were withdrawn after a stabilisation period of 90 days after the initial procedure and post-procedural experienced AF burden. Prior to the outpatient clinic visits at 3, 6 and 12 months, a 7-day auto-triggered event recording was performed using a Vitaphone recorder (Vitaphone GmbH, Mannheim, Germany) [19, 20]. An episode of AF is defined as an episode of at least 30 s’ duration.

Statistical analysis

Results were analysed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Independent samples T-test was used for numerical normally distributed data and the χ2 test
was used for categorical variables. \( P \)-value < 0.05 was considered statistically significant.

## Results

From October 2012 until June 2013, 30 patients were enrolled in the study. Two patients were excluded because PV isolation could not be completed with the cryoballoon alone and additional radiofrequency applications during the same procedure were needed to achieve PV isolation (equal distribution in both groups). Table 1 shows the baseline characteristics. Mean age was 57.3 ± 8.9 years. Hypertension was present in six subjects (21.4%). Mean CHADS2-VASc score was 0.8. Mean corrected left atrial end/diastolic volume was 25.1 ± 7.2 cc/m². Anticoagulation was used by nine patients (32.1%) at the time of randomisation. No significant differences were found between the two operators. Table 2 shows radiation doses and amounts of contrast. Patients in the contrast pulmonary venography group received significantly more contrast agent than subjects in the 3D CT overlay group. Furthermore, patients in the direct fluoroscopy group received more radiation, as expressed in the DAP-value. There were no differences in fluoroscopy time, number of cryoapplications and total procedure time between the two groups. No statistical differences were found.

### Table 1  Baseline characteristics

| Variable                  | Total \( n = 28 \) | 3D CT overlay \( n = 14 \) | Pulmonary Venography \( n = 14 \) | \( p \)-value |
|---------------------------|-------------------|-----------------------------|----------------------------------|--------------|
| Age (years)               | 57.3 ± 8.9        | 58.2 ± 7.6                  | 56.5 ± 10.3                      | ns           |
| Gender (male)             | 20 (71.4%)        | 9 (64.3%)                   | 11 (78.6%)                       | ns           |
| CHADS2-VASc score         | 0.8 ± 1.1         | 0.7 ± 0.7                   | 0.9 ± 1.4                        | ns           |
| Hypertension              | 6 (21.4%)         | 3 (21.4%)                   | 3 (21.4%)                        | ns           |
| Smoking                   | 8 (28.6%)         | 1 (7.1%)                    | 7 (50.0%)                        | 0.011        |
| Diabetes                  | 0 (0%)            | 0 (0%)                      | 0 (0%)                           | –            |
| AF family history <65 years | 9 (32.1%)      | 3 (21.4%)                   | 6 (42.9%)                        | ns           |
| CAD                       | 0 (0%)            | 0 (0%)                      | 0 (0%)                           | –            |
| CHF                       | 0 (0.0%)          | 0 (0.0%)                    | 0 (0.0%)                         | –            |
| Endurance sports          | 3 (10.7%)         | 2 (14.3%)                   | 1 (7.1%)                         | ns           |
| OSAS                      | 1 (3.6%)          | 0 (0.0%)                    | 1 (7.1%)                         | ns           |
| TIA/CVA                   | 1 (3.6%)          | 0 (0.0%)                    | 1 (7.1%)                         | ns           |
| Flutter                   | 3 (10.7%)         | 2 (14.3%)                   | 1 (7.1%)                         | ns           |
| Anticoagulants            | 9 (32.1%)         | 6 (42.9%)                   | 3 (21.4%)                        | ns           |
| No ECV                    | 1.2 ± 1.9         | 1.0 ± 1.7                   | 1.4 ± 2.1                        | ns           |
| BMI                       | 26.8 ± 3.0        | 26.3 ± 2.6                  | 27.2 ± 3.4                       | ns           |
| LA volume (cc/m²)         | 25.1 ± 7.2        | 25.1 ± 6.2                  | 25.1 ± 8.3                       | ns           |

Data are expressed in mean ± SD or absolute number and percentage

AF Atrial fibrillation, CAD Coronary artery disease, CHF Congestive heart failure (Ejection Fraction <40%), OSAS Obstructive sleep apnoea syndrome, TIA Transient ischaemic attack, CVA Cerebral vascular attack, ECV Electrical cardioversion, BMI Body mass index, LA Left atrium, NS Not significant

### Table 2  Procedure results

| Variable                  | Total \( n = 28 \) | 3D CT overlay \( n = 14 \) | Pulmonary Venography \( n = 14 \) | \( p \)-value |
|---------------------------|-------------------|-----------------------------|----------------------------------|--------------|
| Total Contrast used (cc)  | 58.6 (±26.9)      | 40.1 (±17.6)                | 77.1 (±21.2)                     | <0.001       |
| – Without PV angio        | 36.8 (±15.9)      | 40.1 (±17.6)                | 33.4 (±13.8)                     | ns           |
| DAP (Gy.cm²)              | 35.69 (±18.8)     | 28.41 (±11.7)               | 43.0 (±21.9)                     | 0.04         |
| Effective dose procedure (mSv) | 6.71 (±3.5)   | 5.34 (±2.2)                 | 8.08 (±4.1)                      | 0.04         |
| Fluoroscopy time (min)    | 29.4 (±9.8)       | 28.8 (±11.2)                | 30.1 (±8.4)                      | ns           |
| Needle-TSP (min)          | 16.5 (±8.4)       | 14.7 (±3.6)                 | 18.2 (±11.3)                     | ns           |
| Procedure time (min)      | 110.1 (±28.5)     | 113.2 (±36.7)               | 106.9 (±17.8)                    | ns           |
| Cryo-applications per procedure | 9.3 (±2.2)   | 9.9 (±2.7)                  | 8.7 (±1.3)                       | ns           |

Data are expressed in mean ± SD

PV angio Pulmonary vein angiography, DAP Dose area product, TSP Transseptal puncture, NS Not significant
with \( p < 0.05 \) using an intention-to-treat analysis involving all randomised patients.

**Complications**

Complications were present in three patients (10.7%). In one patient (direct fluoroscopy group), the procedure was complicated by permanent vagal nerve injury, resulting in gastric paralysis. One patient (3D CT overlay group) had transient gastric paralysis. One patient (direct fluoroscopy group) suffered from transient right hemidiaphragm paralysis. After the occurrence of vagal nerve injuries, a thermoprobe (SensiTherm, St. Jude Medical, MN, USA) was introduced in our PV procedures to monitor oesophageal temperatures during PV isolation, after which this complication did not longer occur [21].

**Clinical outcome**

At a mean follow-up of 11.9 ± 3.9 months (median 12 months), the success rate without continuation of antiarrhythmic therapy was 78.6% (22 patients). No difference in recurrence of AF was detected between 3D CT overlay and the contrast group (12 vs 10 \( p = 0.55 \)). One patient was lost to follow-up. Four patients were treated in a second procedure using radiofrequency ablation with touch-up of isolation gaps. Successful isolation of all PVs could not be reached in 1 patient, for which a successful video-assisted thoracoscopy PV isolation was performed. Prolonged follow-up for 9.6 ± 3.5 months (median 10 months) showed no recurrence.

**Discussion**

This study shows the feasibility of 3D CT overlay in PV isolation using the cryoballoon and demonstrates significantly less radiation and use of contrast in comparison to contrast pulmonary venography. The use of 3D CT overlay has several benefits over direct fluoroscopy. As the 3D CT overlay image supplies a 3D navigation map, manoeuvring and placing the cryoballoon becomes more straightforward. This has also been demonstrated for 3D transoesophageal echocardiography [11]. The relative difference in radiation dose and radiation time can be explained by the fact that, for cinematographic images of the PV angiograms, a higher resolution was needed.

Contrast-induced acute kidney injury is an important complication of the use of iodinated contrast media, which accounts for a significant number of cases of hospital-acquired acute kidney injury [22]. As PV isolation is increasingly becoming standard therapy for patients with AF, it is essential to optimise patient safety. We realise that a CT scan requires radiation and contrast agent as well. In our study population, a pre-procedural CT scan was performed on all subjects. The amount of contrast agent (Visipaque 320) was 80 or 90 cc. Main dose length product of the CT scan in our study population was 841.3 ± 255.5 mGy.cm. Using the conversion factor of 0.014 mSv Gy\(^{-1}\) cm\(^{-1}\) [17], this results in a main effective dose of 11.8 mSv. The combined effective dose in the 3D CT overlay group is still lower in comparison to that of the direct fluoroscopy group.

However, ideally the radiation and contrast agent necessary for the CT scan is avoided as well. This can be done by using a 3D overlay from magnetic resonance imaging (MRI). Recently, we successfully used a 3D MRI overlay in PV isolation with the cryoballoon in two patients. Although MRI was not used in this study, it could replace the CT scan for the 3D overlay and even further reduce total radiation and contrast dye exposure.

**Conclusion**

The use of 3D CT overlay has several benefits over direct fluoroscopy. As the 3D CT overlay image supplies a 3D navigation map, manoeuvring and placing the cryoballoon becomes more straightforward.

The present study shows that the use of 3D CT overlay has the potential to reduce radiation dose and exposure to contrast dye in cryoballoon-based PV isolation. Even though the study population is limited, the results show a clear benefit of this technique. We expect an additional advantage of 3D MRI overlay with respect to radiation dose. More research into this technique is necessary and will be effectuated.

**Funding** None
Conflict of interest  B. Oude Velthuis, M. Molenaar, H.G. Reinhart Dorman, J.Y. Stevenhagen, M.F. Scholten, J. van der Palen and J.M. van Opstal declare that they have no competing interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Camm AJ, Lip GY, De CR, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europ Heart J. 2012;33(21):2719–47.

2. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66.

3. Cosedis NJ, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367(17):1587–95.

4. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118(24):2498–505.

5. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303(4):333–40.

6. Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713–23.

7. Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm. 2011;8(9):1444–51.

8. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–45.

9. Sarabanda AW, Bunch TJ, Johnson SB, et al. Efficacy and safety of circumferential pulmonary vein isolation using a novel cryothermal balloon ablation system. J Am Coll Cardiol. 2005;46(10):1902–12.

10. Schmidt M, Dorwarth U, Andresen D, et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German ablation registry. J Cardiovasc Electrophysiol. 2014;25(1):1–7.

11. Ottaviano L, Chierchia GB, Bregasi A, et al. Cryoballoon ablation for atrial fibrillation guided by real-time three-dimensional transoesophageal echocardiography: a feasibility study. Europace. 2013;15(7):944–50.

12. Stevenhagen J, Van Der Voort PH, Dekker LR, Bullens RW, Van Den Bosch H, Meijer A. Three-dimensional CT overlay in comparison to CartoMerge for pulmonary vein antrum isolation. J Cardiovasc Electrophysiol. 2010;21(6):634–9.

13. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–420.

14. Oude VB, Stevenhagen J, van Opstal JM, Scholten MF. Continuation of vitamin K antagonists as acceptable anticoagulation regimen in patients undergoing pulmonary vein isolation. Neth Heart J. 2012;20(1):12–5.

15. Andrade JG, Dubuc M, Guerra PG, et al. Pulmonary vein isolation using a second-generation cryoballoon catheter: a randomized comparison of ablation duration and method of deflation. J Cardiovasc Electrophysiol. 2013;24(6):692–8.

16. Schultz FW, Zoetelief J. Dose conversion coefficients for interventional procedures. Radiat Prot Dosimetry. 2005;117(1–3):225–30.

17. K araarslan E, Ulus S, Bavek C. Estimated radiation dose and image quality comparison of the scan protocols in dual-source computed tomography coronary angiography. J Med Imaging Radiat Oncol. 2013;57(4):407–14.

18. Ector J, Dragusin O, Adriaenssens B, et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol. 2007;50(3):234–42.

19. Muller A, Scharner W, Borchardt T, Och W, Korb H. Reliability of an external loop recorder for automatic recognition and transtelephonic ECG transmission of atrial fibrillation. J Telemed Telecare. 2009;15(8):391–6.

20. Velthuis BO, Bos J, Kraaier K, et al. Performance of an external transtelephonic loop recorder for automated detection of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol. 2013;18(6):564–70.

21. Molenaar MMD, Scholten MF, Hesselink T, Stevenhagen YJ, van Opstal JM. High incidence of low esophageal temperatures during cryoballoon therapy for atrial fibrillation. HRS Boston, Ref Type: Abstract, 8-1-2014. 2014.

22. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419–28.

23. Kuwahara T, Takahashi A, Takahashi Y, et al. Clinical characteristics and management of periesophageal vagal nerve injury complicating left atrial ablation of atrial fibrillation: lessons from eleven cases. J Cardiovasc Electrophysiol. 2013;24(8):847–51.

24. Metzner A, Burchard A, Wohlmut P, et al. Increased incidence of esophageal thermal lesions using the second-generation 28-mm cryoballoon. Circ Arrhythm Electrophysiol. 2013;6(4):769–75.